Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tusamitamab ravtansine + sintilimab
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tusamitamab ravtansine + sintilimab is an investigational combination therapy for cancer, primarily being studied in non-small cell lung cancer (NSCLC) and other solid tumors. Tusamitamab ravtansine is an antibody-drug conjugate (ADC) that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), a glycoprotein highly expressed on certain tumor cells. The drug consists of a humanized monoclonal antibody linked to the cytotoxic agent DM4, a maytansinoid that inhibits microtubule assembly, leading to cell-cycle arrest and apoptosis after internalization into CEACAM5-expressing cells[1][3][6]. Sintilimab is a monoclonal antibody targeting programmed death receptor 1 (PD-1), acting as an immune checkpoint inhibitor to enhance antitumor immune responses. This combination aims to leverage direct tumor cell killing by the ADC with immune-mediated effects from PD-1 blockade.
- Other names
- maytansin-loaded anti-ceacam5 mab
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tusamitamab ravtansine + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tusamitamab ravtansine + sintilimab.